TACE, lenvatinib, and PD-1 inhibitors in unresectable advanced hepatocellular carcinoma: an exploratory retrospective cohort study
Hongyi Zhao, Tingting Li, Yu Zhang, Yang Song, Miaomiao Li · 2026
Read TACE, lenvatinib, and PD-1 inhibitors in unresectable advanced hepatocellular carcinoma: an exploratory retrospective cohort study by Hongyi Zhao, Tingting Li, Yu Zhang, Yang Song, Miaomiao Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13479810.txt.
Description
Hongyi Zhao and coauthors published a 2026 cohort study of triple therapy for liver cancer too advanced for surgery. The mix joins chemo delivered into the liver artery, the drug lenvatinib, and immune checkpoint blockers aimed at PD-1. Records covered 209 patients treated from 2016 to 2022, split between dual therapy without immunotherapy and the triple combination.
Math weighting evened the groups on starting gaps before results were compared. Midpoint survival ran about 16.5 months with triple therapy against about 13.4 months with dual therapy in the adjusted look. Tumor shrinkage, treatment dose, and noted side effects were also set side by side. Backward-looking designs leave room for hidden bias, so the authors call the work a first look while reporting a survival hint worth testing in a forward trial.
Catalog record
| CREATOR | Hongyi Zhao, Tingting Li, Yu Zhang, Yang Song, Miaomiao Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51024 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |